Regdanvimab (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Regdanvimab" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

68^th place

28^th place

2businesswire.com

615^th place

3,307^th place

low place

1,569^th place

businesswire.com (Global: 615^th place; Slovenian: 3,307^th place)

»Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform« (tiskovna objava). Celltrion. 11. februar 2021. Pridobljeno 4. marca 2021 – prek Business Wire.
»Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59« (tiskovna objava). Celltrion. 13. januar 2021. Pridobljeno 4. marca 2021 – prek Business Wire.

europa.eu (Global: 68^th place; Slovenian: 28^th place)

ema.europa.eu

»EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19« (tiskovna objava). Evropska agencija za zdravila (EMA). 24. februar 2021. Pridobljeno 4. marca 2021.
https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona, vpogled: 13. 11. 2021.
»EMA review of regdanvimab for COVID-19 to support national decisions on early use« (tiskovna objava). Evropska agencija za zdravila (EMA). 2. marec 2021. Pridobljeno 4. marca 2021.
https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-regkirona-regdanvimab-treating-patients-covid-19, vpogled: 13. 11. 2021.
https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf Povzetek glavnih značilnosti zdravila Regkirona, vpogled: 13. 11. 2021.

jazmp.si (Global: low place; Slovenian: 1,569^th place)

»EMA je izdala nasvet glede uporabe regdanvimaba za zdravljenje COVID-19«. JAZMP. 26. marec 2021. Pridobljeno 28. marca 2021.